person · Reporting owner

GADICKE ANSBERT

Disclosed activity across 13 companies

Tapewire entity: 2481
SEC CIK: 0001134655

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Aktis Oncology, Inc.AKTS · Entity 4711	10% owner	January 12, 2026	January 14, 2026
Cullinan Therapeutics, Inc.CGEM · Entity 4766	10% owner · Former Director	December 31, 2021	February 10, 2023
Dyne Therapeutics, Inc.DYN · Entity 3948	10% owner	September 21, 2020	September 23, 2020
Harpoon Therapeutics, Inc.HARP · Entity 11424	10% owner	May 28, 2021	June 02, 2021
Kalaris Therapeutics, Inc.ALVR · Entity 6805	Director · 10% owner	July 28, 2022	August 01, 2022
Oncorus, Inc.ONCR · Entity 112213	10% owner	October 06, 2020	October 08, 2020
RHYTHM PHARMACEUTICALS, INC.RYTM · Entity 3693	10% owner	October 10, 2017	October 11, 2017
Radius Health, Inc.RDUS · Entity 124173	Director	February 17, 2017	February 22, 2017
Repare Therapeutics Inc.RPTX · Entity 68433	10% owner	July 09, 2021	July 13, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Aktis Oncology, Inc.

Report date January 12, 2026 · Filed January 14, 2026

Jointly reported with MPM ASSET MANAGEMENT LLC, Oncology Impact Private Investment Fund 2, L.P.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	1,655,971	Reported balance After 2026-01-12 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2026-01-12 · Conversion · Acquired 1,314,262 · Balance 1,655,971 F1: The shares of common stock were issued upon conversion as follows: 556,810 by MPM BioVentures 2018, L.P. ("BV 2018"), 29,593 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"), 10,988 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"), 119,478 by MPM Oncology Innovations Fund, L.P. ("MPM Oncology") and 597,393 by Oncology Impact Private Investment Fund 2, L.P. ("MPM Oncology Impact"). MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Drs. Evnin and Gadicke are managing directors of BV 2018 LLC and managers of MPM Oncology Innovations Fund GP LLC, which is the general partner of MPM Oncology. Dr. Gadicke is the managing member of MPM Oncology Investments 2 LLC, which is the general partner of MPM Oncology Impact. F2: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F4: The shares are held as follows: 341,709 by MPM Asset Management LLC ("MPM AM"), 556,810 by BV 2018, 29,593 by BV 2018(B), 10,988 by AM BV2018, 119,478 by MPM Oncology and 597,393 by MPM Oncology Impact. Dr. Gadicke is the manager of MPM AM.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	7,570,168	Reported balance After 2026-01-12 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2026-01-12 · Conversion · Acquired 5,914,197 · Balance 7,570,168 F5: The shares of common stock were issued upon conversion as follows: 2,505,648 by BV 2018, 133,170 by BV 2018(B), 49,452 by AM BV2018, 537,654 by MPM Oncology and 2,688,273 by MPM Oncology Impact. F2: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F6: The shares are held as follows: 341,709 by MPM AM, 3,062,458 by BV 2018, 162,763 by BV 2018(B), 60,440 by AM BV2018, 657,132 by MPM Oncology and 3,285,666 by MPM Oncology Impact.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	9,147,287	Reported balance After 2026-01-12 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2026-01-12 · Conversion · Acquired 1,577,119 · Balance 9,147,287 F7: The shares of common stock were issued upon conversion as follows: 668,173 by BV 2018, 35,512 by BV 2018(B), 13,187 by AM BV2018, 143,374 by MPM Oncology and 716,873 by MPM Oncology Impact. F2: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F8: The shares are held as follows: 341,709 by MPM AM, 3,730,631 by BV 2018, 198,275 by BV 2018(B), 73,627 by AM BV2018, 800,506 by MPM Oncology and 4,002,539 by MPM Oncology Impact.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	10,260,064	Reported balance After 2026-01-12 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2026-01-12 · Purchase · Acquired 1,112,777 · Balance 10,260,064 F9: The shares were purchased as follows: 219,897 by BV 2018, 8,689 by BV 2018(B), 4,284 by AM BV2018, 46,574 by MPM Oncology and 833,333 by MPM Oncology Impact. F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F10: The shares are held as follows: 341,709 by MPM AM, 3,950,528 by BV 2018, 206,964 by BV 2018(B), 77,911 by AM BV2018, 847,080 by MPM Oncology and 4,835,872 by MPM Oncology Impact.
Series Seed Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2026-01-12 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-01-12 · Conversion · Disposed 5,000,000 · Balance 0 F2: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F1: The shares of common stock were issued upon conversion as follows: 556,810 by MPM BioVentures 2018, L.P. ("BV 2018"), 29,593 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"), 10,988 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"), 119,478 by MPM Oncology Innovations Fund, L.P. ("MPM Oncology") and 597,393 by Oncology Impact Private Investment Fund 2, L.P. ("MPM Oncology Impact"). MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Drs. Evnin and Gadicke are managing directors of BV 2018 LLC and managers of MPM Oncology Innovations Fund GP LLC, which is the general partner of MPM Oncology. Dr. Gadicke is the managing member of MPM Oncology Investments 2 LLC, which is the general partner of MPM Oncology Impact. F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
Series A Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2026-01-12 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-01-12 · Conversion · Disposed 22,500,000 · Balance 0 F2: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F5: The shares of common stock were issued upon conversion as follows: 2,505,648 by BV 2018, 133,170 by BV 2018(B), 49,452 by AM BV2018, 537,654 by MPM Oncology and 2,688,273 by MPM Oncology Impact.
Series B Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2026-01-12 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-01-12 · Conversion · Disposed 6,000,000 · Balance 0 F2: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F7: The shares of common stock were issued upon conversion as follows: 668,173 by BV 2018, 35,512 by BV 2018(B), 13,187 by AM BV2018, 143,374 by MPM Oncology and 716,873 by MPM Oncology Impact.

Filing footnotes · ownership attribution and instrument terms

F1: The shares of common stock were issued upon conversion as follows: 556,810 by MPM BioVentures 2018, L.P. ("BV 2018"), 29,593 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"), 10,988 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"), 119,478 by MPM Oncology Innovations Fund, L.P. ("MPM Oncology") and 597,393 by Oncology Impact Private Investment Fund 2, L.P. ("MPM Oncology Impact"). MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Drs. Evnin and Gadicke are managing directors of BV 2018 LLC and managers of MPM Oncology Innovations Fund GP LLC, which is the general partner of MPM Oncology. Dr. Gadicke is the managing member of MPM Oncology Investments 2 LLC, which is the general partner of MPM Oncology Impact.

F2: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date.

F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

F4: The shares are held as follows: 341,709 by MPM Asset Management LLC ("MPM AM"), 556,810 by BV 2018, 29,593 by BV 2018(B), 10,988 by AM BV2018, 119,478 by MPM Oncology and 597,393 by MPM Oncology Impact. Dr. Gadicke is the manager of MPM AM.

F5: The shares of common stock were issued upon conversion as follows: 2,505,648 by BV 2018, 133,170 by BV 2018(B), 49,452 by AM BV2018, 537,654 by MPM Oncology and 2,688,273 by MPM Oncology Impact.

F6: The shares are held as follows: 341,709 by MPM AM, 3,062,458 by BV 2018, 162,763 by BV 2018(B), 60,440 by AM BV2018, 657,132 by MPM Oncology and 3,285,666 by MPM Oncology Impact.

F7: The shares of common stock were issued upon conversion as follows: 668,173 by BV 2018, 35,512 by BV 2018(B), 13,187 by AM BV2018, 143,374 by MPM Oncology and 716,873 by MPM Oncology Impact.

F8: The shares are held as follows: 341,709 by MPM AM, 3,730,631 by BV 2018, 198,275 by BV 2018(B), 73,627 by AM BV2018, 800,506 by MPM Oncology and 4,002,539 by MPM Oncology Impact.

F9: The shares were purchased as follows: 219,897 by BV 2018, 8,689 by BV 2018(B), 4,284 by AM BV2018, 46,574 by MPM Oncology and 833,333 by MPM Oncology Impact.

F10: The shares are held as follows: 341,709 by MPM AM, 3,950,528 by BV 2018, 206,964 by BV 2018(B), 77,911 by AM BV2018, 847,080 by MPM Oncology and 4,835,872 by MPM Oncology Impact.

Cullinan Therapeutics, Inc.

Report date December 31, 2021 · Filed February 10, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	595,489	Reported balance After 2021-12-21 transaction · row 1 1 source row Row 1 · 2021-12-21 · Exercise / conversion · Acquired 350,938 · Balance 595,489
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.30 · Expires 2030-10-28	Direct	0	Reported balance After 2021-12-21 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-12-21 · Exercise / conversion · Disposed 262,114 · Balance 0 F3: These options are fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.30 · Expires 2030-10-28	Direct	0	Reported balance After 2021-12-21 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-12-21 · Exercise / conversion · Disposed 88,824 · Balance 0 F3: These options are fully vested.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	7,648,268	Reported balance Holding disclosure · report date 2021-12-31 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 7,648,268 F1: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F2: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC.

F2: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

F3: These options are fully vested.

Dyne Therapeutics, Inc.

Report date September 21, 2020 · Filed September 23, 2020

Jointly reported with MPM BIOVENTURES 2018, L.P., MPM BIOVENTURES 2018 (B), L.P., MPM ASSET MANAGEMENT INVESTORS BV2018 LLC, MPM BioVentures 2018 GP LLC, MPM BioVentures 2018 LLC, EVNIN LUKE, Foley Todd

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	4,614,943	Reported balance After 2020-09-21 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2020-09-21 · Conversion · Acquired 4,614,943 · Balance 4,614,943 F1: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F5: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2: The shares are held directly by MPM BioVentures 2018, L.P. ("BV 2018"). The general partner of BV 2018 is MPM BioVentures 2018 GP LLC ("BV 2018 GP"). MPM BioVentures 2018 LLC ("BV 2018 LLC") is the managing member of BV 2018 GP. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. Each of BV 2018 GP, BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by BV 2018, except to the extent of its pecuniary interest therein, if any.
Common StockSEC Table I · non-derivative	IndirectSee footnote	245,279	Reported balance After 2020-09-21 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2020-09-21 · Conversion · Acquired 245,279 · Balance 245,279 F1: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F5: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3: The shares are held directly by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"). The general partner of BV 2018(B) is BV 2018 GP. BV 2018 LLC is the managing member of BV 2018 GP. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. Each of BV 2018 GP, BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by BV 2018(B), except to the extent of its pecuniary interest therein, if any.
Common StockSEC Table I · non-derivative	IndirectSee footnote	91,081	Reported balance After 2020-09-21 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2020-09-21 · Conversion · Acquired 91,081 · Balance 91,081 F1: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F5: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F4: The shares are held directly by MPM Asset Management Investors BV2018 LLC ("MPM Asset Management"). The manager of MPM Asset Management is BV 2018 LLC. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV2018 LLC. Each of BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by MPM Asset Management, except to the extent of his pecuniary interest therein, if any.
Series A Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-09-21 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-09-21 · Conversion · Disposed 13,980,992 · Balance 0 F1: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2: The shares are held directly by MPM BioVentures 2018, L.P. ("BV 2018"). The general partner of BV 2018 is MPM BioVentures 2018 GP LLC ("BV 2018 GP"). MPM BioVentures 2018 LLC ("BV 2018 LLC") is the managing member of BV 2018 GP. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. Each of BV 2018 GP, BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by BV 2018, except to the extent of its pecuniary interest therein, if any.
Series A Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-09-21 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-09-21 · Conversion · Disposed 743,076 · Balance 0 F1: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3: The shares are held directly by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"). The general partner of BV 2018(B) is BV 2018 GP. BV 2018 LLC is the managing member of BV 2018 GP. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. Each of BV 2018 GP, BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by BV 2018(B), except to the extent of its pecuniary interest therein, if any.
Series A Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-09-21 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-09-21 · Conversion · Disposed 275,932 · Balance 0 F1: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F4: The shares are held directly by MPM Asset Management Investors BV2018 LLC ("MPM Asset Management"). The manager of MPM Asset Management is BV 2018 LLC. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV2018 LLC. Each of BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by MPM Asset Management, except to the extent of his pecuniary interest therein, if any.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-09-21 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-09-21 · Conversion · Disposed 1,326,313 · Balance 0 F5: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2: The shares are held directly by MPM BioVentures 2018, L.P. ("BV 2018"). The general partner of BV 2018 is MPM BioVentures 2018 GP LLC ("BV 2018 GP"). MPM BioVentures 2018 LLC ("BV 2018 LLC") is the managing member of BV 2018 GP. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. Each of BV 2018 GP, BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by BV 2018, except to the extent of its pecuniary interest therein, if any.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-09-21 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2020-09-21 · Conversion · Disposed 70,492 · Balance 0 F5: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3: The shares are held directly by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"). The general partner of BV 2018(B) is BV 2018 GP. BV 2018 LLC is the managing member of BV 2018 GP. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. Each of BV 2018 GP, BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by BV 2018(B), except to the extent of its pecuniary interest therein, if any.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-09-21 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2020-09-21 · Conversion · Disposed 26,176 · Balance 0 F5: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F4: The shares are held directly by MPM Asset Management Investors BV2018 LLC ("MPM Asset Management"). The manager of MPM Asset Management is BV 2018 LLC. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV2018 LLC. Each of BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by MPM Asset Management, except to the extent of his pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.

F2: The shares are held directly by MPM BioVentures 2018, L.P. ("BV 2018"). The general partner of BV 2018 is MPM BioVentures 2018 GP LLC ("BV 2018 GP"). MPM BioVentures 2018 LLC ("BV 2018 LLC") is the managing member of BV 2018 GP. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. Each of BV 2018 GP, BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by BV 2018, except to the extent of its pecuniary interest therein, if any.

F3: The shares are held directly by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"). The general partner of BV 2018(B) is BV 2018 GP. BV 2018 LLC is the managing member of BV 2018 GP. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. Each of BV 2018 GP, BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by BV 2018(B), except to the extent of its pecuniary interest therein, if any.

F4: The shares are held directly by MPM Asset Management Investors BV2018 LLC ("MPM Asset Management"). The manager of MPM Asset Management is BV 2018 LLC. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV2018 LLC. Each of BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by MPM Asset Management, except to the extent of his pecuniary interest therein, if any.

F5: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.

Harpoon Therapeutics, Inc.

Report date May 28, 2021 · Filed June 02, 2021

Jointly reported with Oncology Impact Fund (Cayman) Management L.P., MPM BIOIMPACT LLC, MPM Oncology Impact Management GP LLC, UBS Oncology Impact Fund L.P.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	6,374,904	Reported balance After 2021-05-28 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2021-05-28 · Sale · Disposed 10,685 · Balance 6,374,904 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F2: The shares were sold as follows: 9,392 by UBS Oncology Impact Fund, L.P. ("UBS Oncology") and 1,293 by MPM Asset Management LLC ("AM LLC"). F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.52 to $21.50 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4: The shares are held as follows: 2,657,097 by MPM BioVentures 2014, L.P. ("BV 2014"), 152,470 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 96,376 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 231,110 by AM LLC and 3,237,851 by UBS Oncology. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. BV LLC is the manager of AM BV2014. Messrs. Evnin, Gadicke and Foley are the members of BV LLC and Messrs. Evnin and Gadicke are the members of AM LLC. Mr. Gadicke is the Managing Member of Oncology GP LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	6,371,804	Reported balance After 2021-05-28 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2021-05-28 · Sale · Disposed 3,100 · Balance 6,371,804 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F5: The shares were sold as follows: 2,725 by UBS Oncology and 375 by AM LLC. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.58 to $22.50 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F7: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 230,735 by AM LLC and 3,235,126 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	6,371,704	Reported balance After 2021-05-28 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2021-05-28 · Sale · Disposed 100 · Balance 6,371,704 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F8: The shares were sold as follows: 88 by UBS Oncology and 12 by AM LLC. F9: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 230,723 by AM LLC and 3,235,038 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	6,353,213	Reported balance After 2021-06-01 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2021-06-01 · Sale · Disposed 18,491 · Balance 6,353,213 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F10: The shares were sold as follows: 16,253 by UBS Oncology and 2,238 by AM LLC. F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.74 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F12: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 228,485 by AM LLC and 3,218,785 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	6,328,095	Reported balance After 2021-06-02 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 5 · 2021-06-02 · Sale · Disposed 25,118 · Balance 6,328,095 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F13: The shares were sold as follows: 22,078 by UBS Oncology and 3,040 by AM LLC. F14: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.24 to $20.76 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F15: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 225,445 by AM LLC and 3,196,707 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021.

F2: The shares were sold as follows: 9,392 by UBS Oncology Impact Fund, L.P. ("UBS Oncology") and 1,293 by MPM Asset Management LLC ("AM LLC").

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.52 to $21.50 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The shares are held as follows: 2,657,097 by MPM BioVentures 2014, L.P. ("BV 2014"), 152,470 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 96,376 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 231,110 by AM LLC and 3,237,851 by UBS Oncology. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. BV LLC is the manager of AM BV2014. Messrs. Evnin, Gadicke and Foley are the members of BV LLC and Messrs. Evnin and Gadicke are the members of AM LLC. Mr. Gadicke is the Managing Member of Oncology GP LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

F5: The shares were sold as follows: 2,725 by UBS Oncology and 375 by AM LLC.

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.58 to $22.50 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F7: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 230,735 by AM LLC and 3,235,126 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

F8: The shares were sold as follows: 88 by UBS Oncology and 12 by AM LLC.

F9: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 230,723 by AM LLC and 3,235,038 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

F10: The shares were sold as follows: 16,253 by UBS Oncology and 2,238 by AM LLC.

F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.74 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F12: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 228,485 by AM LLC and 3,218,785 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

F13: The shares were sold as follows: 22,078 by UBS Oncology and 3,040 by AM LLC.

F14: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.24 to $20.76 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F15: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 225,445 by AM LLC and 3,196,707 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

Kalaris Therapeutics, Inc.

Report date July 28, 2022 · Filed August 01, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy ElevateBio LLC	16,674,766	Reported balance After 2022-07-28 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2022-07-28 · Grant · Acquired 3,253,796 · Balance 16,674,766 F1: On July 28, 2022, ElevateBio LLC ("ElevateBio") acquired 3,253,796 shares of the Issuer's Common Stock in a registered direct offering for a purchase price of $4.61 per share. F2: Shares held by ElevateBio. The Reporting Person is a director of ElevateBio, and may be deemed to have shared voting and investment power of the shares held by ElevateBio. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	Direct	30,197	Reported balance Holding disclosure · report date 2022-07-28 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 30,197

Filing footnotes · ownership attribution and instrument terms

F1: On July 28, 2022, ElevateBio LLC ("ElevateBio") acquired 3,253,796 shares of the Issuer's Common Stock in a registered direct offering for a purchase price of $4.61 per share.

F2: Shares held by ElevateBio. The Reporting Person is a director of ElevateBio, and may be deemed to have shared voting and investment power of the shares held by ElevateBio. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Oncorus, Inc.

Report date October 06, 2020 · Filed October 08, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	1,899,702	Reported balance After 2020-10-06 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2020-10-06 · Conversion · Acquired 1,783,879 · Balance 1,899,702 F1: Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F2: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F3: The shares are held as follows: 1,382,943 by MPM BioVentures 2014, L.P. ("BV 2014"), 92,239 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 50,164 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 224,924 by MPM Sunstates Fund, L.P. ("MPM SunStates"), 33,609 by MPM Asset Management Investors Sunstates Fund LLC ("AM SunStates") and 115,823 by MPM Asset Management LLC ("AM LLC"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM SunStates Fund GP LLC and MPM SunStates GP Managing Member LLC ("SunStates GP") are the direct and indirect general partners of MPM SunStates. SunStates GP is the manager of AM SunStates. Luke Evnin, Ansbert Gadicke and Todd Foley are the managing directors of BV LLC, Luke Evnin and Anbsert Gadicke are the members of AM LLC and Ansbert Gadicke is a member of SunStates GP.
Common StockSEC Table I · non-derivative	IndirectSee footnote	1,525,348	Reported balance After 2020-10-06 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2020-10-06 · Conversion · Acquired 1,525,348 · Balance 1,525,348 F1: Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F2: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F4: The reported securities are held in the account of UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing member of Oncology GP LLC.
Common StockSEC Table I · non-derivative	IndirectSee footnote	2,675,677	Reported balance After 2020-10-06 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2020-10-06 · Conversion · Acquired 775,975 · Balance 2,675,677 F1: Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F2: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F5: The shares are held as follows: 2,018,001 by BV 2014, 134,595 by BV 2014(B), 73,199 by AM BV2014, 290,632 by MPM SunStates, 43,427 by AM SunStates and 115,823 by AM LLC.
Common StockSEC Table I · non-derivative	IndirectSee footnote	2,225,801	Reported balance After 2020-10-06 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2020-10-06 · Conversion · Acquired 700,453 · Balance 2,225,801 F1: Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F2: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F4: The reported securities are held in the account of UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing member of Oncology GP LLC.
Common StockSEC Table I · non-derivative	IndirectSee footnote	2,849,453	Reported balance After 2020-10-06 transaction · row 5 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 5 · 2020-10-06 · Purchase · Acquired 173,776 · Balance 2,849,453 F2: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F6: The shares are held as follows: 2,155,108 by BV 2014, 143,740 by BV 2014(B), 78,172 by AM BV2014, 310,251 by MPM SunStates, 46,359 by AM SunStates and 115,823 by AM LLC.
Common StockSEC Table I · non-derivative	IndirectSee footnote	2,377,025	Reported balance After 2020-10-06 transaction · row 6 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 6 · 2020-10-06 · Purchase · Acquired 151,224 · Balance 2,377,025 F2: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F4: The reported securities are held in the account of UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing member of Oncology GP LLC.
Series A-1 Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-10-06 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-10-06 · Conversion · Acquired 1,783,879 · Balance 0 F1: Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F2: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F7: The shares are held as follows: 1,382,943 by BV 2014, 92,239 by BV 2014(B), 50,164 by AM BV2014, 224,924 by MPM SunStates and 33,609 by AM SunStates.
Series A-1 Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-10-06 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2020-10-06 · Conversion · Acquired 1,525,348 · Balance 0 F1: Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F2: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F4: The reported securities are held in the account of UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing member of Oncology GP LLC.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-10-06 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2020-10-06 · Conversion · Acquired 775,975 · Balance 0 F1: Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F2: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F8: The shares are held as follows: 635,058 by BV 2014, 42,356 by BV 2014(B), 23,035 by AM BV2014, 65,708 by MPM SunStates and 9,818 by AM SunStates.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-10-06 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2020-10-06 · Conversion · Acquired 700,453 · Balance 0 F1: Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F2: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F4: The reported securities are held in the account of UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing member of Oncology GP LLC.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date.

F2: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

F3: The shares are held as follows: 1,382,943 by MPM BioVentures 2014, L.P. ("BV 2014"), 92,239 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 50,164 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 224,924 by MPM Sunstates Fund, L.P. ("MPM SunStates"), 33,609 by MPM Asset Management Investors Sunstates Fund LLC ("AM SunStates") and 115,823 by MPM Asset Management LLC ("AM LLC"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM SunStates Fund GP LLC and MPM SunStates GP Managing Member LLC ("SunStates GP") are the direct and indirect general partners of MPM SunStates. SunStates GP is the manager of AM SunStates. Luke Evnin, Ansbert Gadicke and Todd Foley are the managing directors of BV LLC, Luke Evnin and Anbsert Gadicke are the members of AM LLC and Ansbert Gadicke is a member of SunStates GP.

F4: The reported securities are held in the account of UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing member of Oncology GP LLC.

F5: The shares are held as follows: 2,018,001 by BV 2014, 134,595 by BV 2014(B), 73,199 by AM BV2014, 290,632 by MPM SunStates, 43,427 by AM SunStates and 115,823 by AM LLC.

F6: The shares are held as follows: 2,155,108 by BV 2014, 143,740 by BV 2014(B), 78,172 by AM BV2014, 310,251 by MPM SunStates, 46,359 by AM SunStates and 115,823 by AM LLC.

F7: The shares are held as follows: 1,382,943 by BV 2014, 92,239 by BV 2014(B), 50,164 by AM BV2014, 224,924 by MPM SunStates and 33,609 by AM SunStates.

F8: The shares are held as follows: 635,058 by BV 2014, 42,356 by BV 2014(B), 23,035 by AM BV2014, 65,708 by MPM SunStates and 9,818 by AM SunStates.

RHYTHM PHARMACEUTICALS, INC.

Report date October 10, 2017 · Filed October 11, 2017

Jointly reported with MPM BIOVENTURES V, L.P., EVNIN LUKE, MPM ASSET MANAGEMENT INVESTORS BV5 LLC, MPM BIOVENTURES V GP LLC, MPM BIOVENTURES V LLC

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	2,596,392	Reported balance After 2017-10-10 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2017-10-10 · Conversion · Acquired 2,567,014 · Balance 2,596,392 F1: Each share of preferred stock converted into approximately 0.10905125 shares of common stock upon the closing of the issuer's initial public offering. The shares had no expiration date. F2: The shares are held as follows: 2,499,299 by MPM BioVentures V, L.P. ("BV V") and 97,093 by MPM Asset Management Investors BV5 LLC ("AM BV5"). MPM BioVentures V GP LLC and MPM BioVentures V LLC ("BV LLC") are the direct and indirect general partners of BV V and BV LLC is the manager of AM BV5. Ansbert Gadicke, Luke Evnin and Todd Foley are the members of BV LLC. Mr. Foley is a director of the Issuer and has separately filed a Form 4. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	2,696,392	Reported balance After 2017-10-10 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2017-10-10 · Purchase · Acquired 100,000 · Balance 2,696,392 F3: Shares were purchased as follows: 96,260 by BV V and 3,740 by AM BV5. F4: Shares are held as follows: 2,595,559 by BV V and 100,833 by AM BV5. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
Series A Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2017-10-10 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-10-10 · Conversion · Disposed 7,651,831 · Balance 0 F1: Each share of preferred stock converted into approximately 0.10905125 shares of common stock upon the closing of the issuer's initial public offering. The shares had no expiration date. F5: The shares of Series A Preferred Stock were held as follows: 7,365,688 by BV V and 286,143 by AM BV5.
Series A-1 Junior Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2017-10-10 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2017-10-10 · Conversion · Disposed 15,887,703 · Balance 0 F1: Each share of preferred stock converted into approximately 0.10905125 shares of common stock upon the closing of the issuer's initial public offering. The shares had no expiration date. F6: The shares of Series A-1 Junior Preferred Stock were held as follows: 15,293,569 by BV V and 594,134 by AM BV5.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of preferred stock converted into approximately 0.10905125 shares of common stock upon the closing of the issuer's initial public offering. The shares had no expiration date.

F2: The shares are held as follows: 2,499,299 by MPM BioVentures V, L.P. ("BV V") and 97,093 by MPM Asset Management Investors BV5 LLC ("AM BV5"). MPM BioVentures V GP LLC and MPM BioVentures V LLC ("BV LLC") are the direct and indirect general partners of BV V and BV LLC is the manager of AM BV5. Ansbert Gadicke, Luke Evnin and Todd Foley are the members of BV LLC. Mr. Foley is a director of the Issuer and has separately filed a Form 4. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.

F3: Shares were purchased as follows: 96,260 by BV V and 3,740 by AM BV5.

F4: Shares are held as follows: 2,595,559 by BV V and 100,833 by AM BV5. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.

F5: The shares of Series A Preferred Stock were held as follows: 7,365,688 by BV V and 286,143 by AM BV5.

F6: The shares of Series A-1 Junior Preferred Stock were held as follows: 15,293,569 by BV V and 594,134 by AM BV5.

Radius Health, Inc.

Report date February 17, 2017 · Filed February 22, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $45.65 · Expires 2027-02-16	Direct	27,500	Reported balance After 2017-02-17 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2017-02-17 · Grant · Acquired 27,500 · Balance 27,500 F1: The option vests in full on February 17, 2018, subject to continued service to the Issuer through such date.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests in full on February 17, 2018, subject to continued service to the Issuer through such date.

Repare Therapeutics Inc.

Report date July 09, 2021 · Filed July 13, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common SharesSEC Table I · non-derivative	IndirectSee Footnote	3,940,497	Reported balance After 2021-07-09 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2021-07-09 · Sale · Disposed 4,067 · Balance 3,940,497 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F2: The shares were sold as follows: 1,732 by MPM BioVentures 2014, L.P. ("BV 2014"), 60 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 2,275 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.95 to $33.20 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4: The shares are held as follows: 2,061,400 by BV 2014, 135,843 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 70,952 by AM BV2014 and 1,672,302 by UBS Oncology. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Ansbert Gadicke is a managing director of BV LLC. MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is the Managing Member of Oncology GP LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
Common SharesSEC Table I · non-derivative	IndirectSee Footnote	3,883,196	Reported balance After 2021-07-12 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2021-07-12 · Sale · Disposed 57,301 · Balance 3,883,196 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F5: The shares were sold as follows: 24,408 by BV 2014, 838 by AM BV2014 and 32,055 by UBS Oncology. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.05 to $34.04 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F7: The shares are held as follows: 2,036,992 by BV 2014, 135,843 by BV 2014(B), 70,114 by AM BV2014 and 1,640,247 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
Common SharesSEC Table I · non-derivative	IndirectSee Footnote	3,882,485	Reported balance After 2021-07-12 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2021-07-12 · Sale · Disposed 711 · Balance 3,882,485 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F8: The shares were sold as follows: 303 by BV 2014, 10 by AM BV2014 and 398 by UBS Oncology. F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.055 to $34.135 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F10: The shares are held as follows: 2,036,689 by BV 2014, 135,843 by BV 2014(B), 70,104 by AM BV2014 and 1,639,849 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021.

F2: The shares were sold as follows: 1,732 by MPM BioVentures 2014, L.P. ("BV 2014"), 60 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 2,275 by UBS Oncology Impact Fund L.P. ("UBS Oncology").

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.95 to $33.20 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The shares are held as follows: 2,061,400 by BV 2014, 135,843 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 70,952 by AM BV2014 and 1,672,302 by UBS Oncology. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Ansbert Gadicke is a managing director of BV LLC. MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is the Managing Member of Oncology GP LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

F5: The shares were sold as follows: 24,408 by BV 2014, 838 by AM BV2014 and 32,055 by UBS Oncology.

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.05 to $34.04 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F7: The shares are held as follows: 2,036,992 by BV 2014, 135,843 by BV 2014(B), 70,114 by AM BV2014 and 1,640,247 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

F8: The shares were sold as follows: 303 by BV 2014, 10 by AM BV2014 and 398 by UBS Oncology.

F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.055 to $34.135 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F10: The shares are held as follows: 2,036,689 by BV 2014, 135,843 by BV 2014(B), 70,104 by AM BV2014 and 1,639,849 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

Past disclosures · reporting ended (4)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Entrada Therapeutics, Inc.

Report date September 04, 2026 · Filed September 09, 2026

Jointly reported with MPM BioVentures 2014, L.P., EVNIN LUKE, Foley Todd, MPM BioVentures 2014 (B), L.P., MPM Asset Management Investors BV2014 LLC, MPM BioVentures 2014 LLC, MPM BioVentures 2014 GP LLC, MPM BIOVENTURES 2018 (B), L.P., MPM ASSET MANAGEMENT INVESTORS BV2018 LLC

Section 16 reporting ended · disclosed 2026-09-09. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	4,106,452	Reported balance After 2026-09-04 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2026-09-04 · Sale · Disposed 38,500 · Balance 4,106,452 F1: The shares were sold as follows: 17,482 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,166 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 602 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 17,942 by MPM BioVentures 2018, L.P. ("BV 2018"), 954 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 354 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC. F2: Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.01 to $7.16 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F3: The shares are held as follows: 1,864,673 by BV 2014, 124,370 by BV 2014(B), 64,182 by AM BV2014, 1,913,743 by BV 2018, 101,714 by BV 2018(B) and 37,770 by AM BV2018. F4: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	3,913,952	Reported balance After 2026-09-08 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2026-09-08 · Sale · Disposed 192,500 · Balance 3,913,952 F5: The shares were sold as follows: 87,411 by BV 2014, 5,830 by BV 2014(B), 3,009 by AM BV2014, 89,712 by BV 2018, 4,768 by BV 2018(B) and 1,770 by AM BV2018. F6: Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.97 to $7.70 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F4: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. F7: The shares are held as follows: 1,777,262 by BV 2014, 118,540 by BV 2014(B), 61,173 by AM BV2014, 1,824,031 by BV 2018, 96,946 by BV 2018(B) and 36,000 by AM BV2018.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	3,885,115	Reported balance After 2026-09-09 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2026-09-09 · Sale · Disposed 28,837 · Balance 3,885,115 F8: The shares were sold as follows: 13,095 by BV 2014, 873 by BV 2014(B), 451 by AM BV2014, 13,439 by BV 2018, 714 by BV 2018(B) and 265 by AM BV2018. F9: Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.02 to $7.54 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F4: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. F10: The shares are held as follows: 1,764,167 by BV 2014, 117,667 by BV 2014(B), 60,722 by AM BV2014, 1,810,592 by BV 2018, 96,232 by BV 2018(B) and 35,735 by AM BV2018.

Filing footnotes · ownership attribution and instrument terms

F1: The shares were sold as follows: 17,482 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,166 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 602 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 17,942 by MPM BioVentures 2018, L.P. ("BV 2018"), 954 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 354 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC.

F2: Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.01 to $7.16 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

F3: The shares are held as follows: 1,864,673 by BV 2014, 124,370 by BV 2014(B), 64,182 by AM BV2014, 1,913,743 by BV 2018, 101,714 by BV 2018(B) and 37,770 by AM BV2018.

F4: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.

F5: The shares were sold as follows: 87,411 by BV 2014, 5,830 by BV 2014(B), 3,009 by AM BV2014, 89,712 by BV 2018, 4,768 by BV 2018(B) and 1,770 by AM BV2018.

F6: Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.97 to $7.70 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

F7: The shares are held as follows: 1,777,262 by BV 2014, 118,540 by BV 2014(B), 61,173 by AM BV2014, 1,824,031 by BV 2018, 96,946 by BV 2018(B) and 36,000 by AM BV2018.

F8: The shares were sold as follows: 13,095 by BV 2014, 873 by BV 2014(B), 451 by AM BV2014, 13,439 by BV 2018, 714 by BV 2018(B) and 265 by AM BV2018.

F9: Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.02 to $7.54 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

F10: The shares are held as follows: 1,764,167 by BV 2014, 117,667 by BV 2014(B), 60,722 by AM BV2014, 1,810,592 by BV 2018, 96,232 by BV 2018(B) and 35,735 by AM BV2018.

TCR2 THERAPEUTICS INC.

Report date June 01, 2023 · Filed June 05, 2023

Section 16 reporting ended · disclosed 2023-06-05. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	Reported balance After 2023-06-01 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2023-06-01 · Other · Disposed 304,001 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time"). F2: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares"). F3: The shares were held by MPM Asset Management LLC ("AM LLC"). The reporting person is a member of AM LLC and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	Reported balance After 2023-06-01 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2023-06-01 · Other · Disposed 3,854,963 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time"). F2: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares"). F4: The shares were held as follows: 3,056,272 by MPM BioVentures 2014, L.P. ("BV 2014"), 203,846 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 110,859 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 421,070 by MPM SunStates Fund, L.P. ("MPM SunStates") and 62,916 by MPM Asset Management Investors Sunstates Fund LLC ("AM SunStates"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B) and BV LLC is the manager of AM BV2014. MPM SunStates Fund GP LLC and MPM SunStates GP Managing Member LLC ("SunStates GP") are the direct and indirect general partners of MPM SunStates and SunStates GP is the manager of AM SunStates. The reporting person is a managing director of BV LLC and a member of SunStates GP and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	Reported balance After 2023-06-01 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2023-06-01 · Other · Disposed 3,370,982 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time"). F2: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares"). F5: The shares were held by UBS Oncology Impact Fund L.P. ("UBS Oncology"). BioImpact Capital LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. The reporting person is the managing partner of BioImpact and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time").

F2: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares").

F3: The shares were held by MPM Asset Management LLC ("AM LLC"). The reporting person is a member of AM LLC and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

F4: The shares were held as follows: 3,056,272 by MPM BioVentures 2014, L.P. ("BV 2014"), 203,846 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 110,859 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 421,070 by MPM SunStates Fund, L.P. ("MPM SunStates") and 62,916 by MPM Asset Management Investors Sunstates Fund LLC ("AM SunStates"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B) and BV LLC is the manager of AM BV2014. MPM SunStates Fund GP LLC and MPM SunStates GP Managing Member LLC ("SunStates GP") are the direct and indirect general partners of MPM SunStates and SunStates GP is the manager of AM SunStates. The reporting person is a managing director of BV LLC and a member of SunStates GP and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

F5: The shares were held by UBS Oncology Impact Fund L.P. ("UBS Oncology"). BioImpact Capital LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. The reporting person is the managing partner of BioImpact and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

Werewolf Therapeutics, Inc.

Report date December 02, 2025 · Filed December 04, 2025

Jointly reported with MPM ONCOLOGY INNOVATIONS FUND LP, UBS Oncology Impact Fund L.P., Oncology Impact Fund (Cayman) Management L.P., MPM BIOIMPACT LLC, MPM Oncology Innovations Fund GP LLC, MPM ASSET MANAGEMENT LLC

Section 16 reporting ended · disclosed 2025-12-04. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	4,924,566	Reported balance After 2025-12-02 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2025-12-02 · Sale · Disposed 59,277 · Balance 4,924,566 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F2: The shares were sold as follows: 4,070 by MPM Asset Management LLC ("AM LLC"), 25,712 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,715 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 884 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 5,662 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 21,234 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.852 to $0.9246 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F5: The shares are held as follows: 338,231 by AM LLC, 2,135,926 by BV 2014, 142,463 by BV 2014(B), 73,518 by AM BV2014, 468,282 by MPM OIF and 1,766,146 by UBS Oncology.
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	4,867,341	Reported balance After 2025-12-03 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2025-12-03 · Sale · Disposed 57,225 · Balance 4,867,341 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F6: The shares were sold as follows: 3,929 by AM LLC, 24,821 by BV 2014, 1,656 by BV 2014(B), 854 by AM BV2014, 5,466 by MPM OIF and 20,499 by UBS Oncology. F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.9256 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F8: The shares are held as follows: 334,302 by AM LLC, 2,111,105 by BV 2014, 140,807 by BV 2014(B), 72,664 by AM BV2014, 462,816 by MPM OIF and 1,745,647 by UBS Oncology.
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	4,784,111	Reported balance After 2025-12-04 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2025-12-04 · Sale · Disposed 83,230 · Balance 4,784,111 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F9: The shares were sold as follows: 5,714 by AM LLC, 36,101 by BV 2014, 2,408 by BV 2014(B), 1,243 by AM BV2014, 7,950 by MPM OIF and 29,814 by UBS Oncology. F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.92 to $1.0208 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F11: The shares are held as follows: 328,588 by AM LLC, 2,075,004 by BV 2014, 138,399 by BV 2014(B), 71,421 by AM BV2014, 454,866 by MPM OIF and 1,715,833 by UBS Oncology.

Filing footnotes · ownership attribution and instrument terms

F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.

F2: The shares were sold as follows: 4,070 by MPM Asset Management LLC ("AM LLC"), 25,712 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,715 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 884 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 5,662 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 21,234 by UBS Oncology Impact Fund L.P. ("UBS Oncology").

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.852 to $0.9246 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

F5: The shares are held as follows: 338,231 by AM LLC, 2,135,926 by BV 2014, 142,463 by BV 2014(B), 73,518 by AM BV2014, 468,282 by MPM OIF and 1,766,146 by UBS Oncology.

F6: The shares were sold as follows: 3,929 by AM LLC, 24,821 by BV 2014, 1,656 by BV 2014(B), 854 by AM BV2014, 5,466 by MPM OIF and 20,499 by UBS Oncology.

F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.9256 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F8: The shares are held as follows: 334,302 by AM LLC, 2,111,105 by BV 2014, 140,807 by BV 2014(B), 72,664 by AM BV2014, 462,816 by MPM OIF and 1,745,647 by UBS Oncology.

F9: The shares were sold as follows: 5,714 by AM LLC, 36,101 by BV 2014, 2,408 by BV 2014(B), 1,243 by AM BV2014, 7,950 by MPM OIF and 29,814 by UBS Oncology.

F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.92 to $1.0208 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F11: The shares are held as follows: 328,588 by AM LLC, 2,075,004 by BV 2014, 138,399 by BV 2014(B), 71,421 by AM BV2014, 454,866 by MPM OIF and 1,715,833 by UBS Oncology.

iTeos Therapeutics, Inc.

Report date May 13, 2025 · Filed May 15, 2025

Jointly reported with MPM BIOIMPACT LLC, Oncology Impact Fund (Cayman) Management L.P., UBS Oncology Impact Fund L.P.

Section 16 reporting ended · disclosed 2025-05-15. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	3,452,797	Reported balance After 2025-05-13 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2025-05-13 · Sale · Disposed 1,031,931 · Balance 3,452,797 F1: The shares were sold as follows: 355,406 by MPM BioVentures 2014, L.P. ("BV 2014"), 22,386 by MPM BioVentures 2014 (B), L.P. ("BV 2014(B)"), 12,233 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 224,467 by MPM BioVentures 2018, L.P. ("BV 2018"), 11,267 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)"), 4,432 by MPM Asset Management Investors BV2018 LLC ("AM BV2018") and 401,740 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC. F2: MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.73 to $8.34 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4: The shares are held as follows: 1,189,174 by BV 2014, 74,903 by BV 2014(B), 40,931 by AM BV2014, 751,056 by BV 2018, 37,699 by BV 2018(B), 14,831 by AM BV2018 and 1,344,203 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: The shares were sold as follows: 355,406 by MPM BioVentures 2014, L.P. ("BV 2014"), 22,386 by MPM BioVentures 2014 (B), L.P. ("BV 2014(B)"), 12,233 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 224,467 by MPM BioVentures 2018, L.P. ("BV 2018"), 11,267 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)"), 4,432 by MPM Asset Management Investors BV2018 LLC ("AM BV2018") and 401,740 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC.

F2: MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.73 to $8.34 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The shares are held as follows: 1,189,174 by BV 2014, 74,903 by BV 2014(B), 40,931 by AM BV2014, 751,056 by BV 2018, 37,699 by BV 2018(B), 14,831 by AM BV2018 and 1,344,203 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 09, 2026 Filed Sep 9, 2026 23:23 UTC	Entrada Therapeutics, Inc. TRDA · Entity 2163	SaleCommon Stock	28,837	$7.13	$205,607.81	Disclosure SEC source: 0001231919-26-001155 · form4-09092026_110922.xml · nonDerivative · entry 3 MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner EVNIN LUKE · CIK 0001134657 · 10% owner GADICKE ANSBERT · CIK 0001134655 · 10% owner Foley Todd · CIK 0001473930 · 10% owner MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner MPM BIOVENTURES 2018 (B), L.P. · CIK 0001729504 · 10% owner MPM ASSET MANAGEMENT INVESTORS BV2018 LLC · CIK 0001734817 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 3,885,115 F8 · shares: The shares were sold as follows: 13,095 by BV 2014, 873 by BV 2014(B), 451 by AM BV2014, 13,439 by BV 2018, 714 by BV 2018(B) and 265 by AM BV2018. F9 · price: Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.02 to $7.54 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F4 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. F10 · ownership.nature: The shares are held as follows: 1,764,167 by BV 2014, 117,667 by BV 2014(B), 60,722 by AM BV2014, 1,810,592 by BV 2018, 96,232 by BV 2018(B) and 35,735 by AM BV2018. Read SEC document
September 08, 2026 Filed Sep 9, 2026 23:23 UTC	Entrada Therapeutics, Inc. TRDA · Entity 2163	SaleCommon Stock	192,500	$7.41	$1,426,425.00	Disclosure SEC source: 0001231919-26-001155 · form4-09092026_110922.xml · nonDerivative · entry 2 MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner EVNIN LUKE · CIK 0001134657 · 10% owner GADICKE ANSBERT · CIK 0001134655 · 10% owner Foley Todd · CIK 0001473930 · 10% owner MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner MPM BIOVENTURES 2018 (B), L.P. · CIK 0001729504 · 10% owner MPM ASSET MANAGEMENT INVESTORS BV2018 LLC · CIK 0001734817 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 3,913,952 F5 · shares: The shares were sold as follows: 87,411 by BV 2014, 5,830 by BV 2014(B), 3,009 by AM BV2014, 89,712 by BV 2018, 4,768 by BV 2018(B) and 1,770 by AM BV2018. F6 · price: Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.97 to $7.70 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F4 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. F7 · ownership.nature: The shares are held as follows: 1,777,262 by BV 2014, 118,540 by BV 2014(B), 61,173 by AM BV2014, 1,824,031 by BV 2018, 96,946 by BV 2018(B) and 36,000 by AM BV2018. Read SEC document
September 04, 2026 Filed Sep 9, 2026 23:23 UTC	Entrada Therapeutics, Inc. TRDA · Entity 2163	SaleCommon Stock	38,500	$7.11	$273,735.00	Disclosure SEC source: 0001231919-26-001155 · form4-09092026_110922.xml · nonDerivative · entry 1 MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner EVNIN LUKE · CIK 0001134657 · 10% owner GADICKE ANSBERT · CIK 0001134655 · 10% owner Foley Todd · CIK 0001473930 · 10% owner MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner MPM BIOVENTURES 2018 (B), L.P. · CIK 0001729504 · 10% owner MPM ASSET MANAGEMENT INVESTORS BV2018 LLC · CIK 0001734817 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 4,106,452 F1 · shares: The shares were sold as follows: 17,482 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,166 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 602 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 17,942 by MPM BioVentures 2018, L.P. ("BV 2018"), 954 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 354 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC. F2 · price: Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.01 to $7.16 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F3 · ownership.nature: The shares are held as follows: 1,864,673 by BV 2014, 124,370 by BV 2014(B), 64,182 by AM BV2014, 1,913,743 by BV 2018, 101,714 by BV 2018(B) and 37,770 by AM BV2018. F4 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. Read SEC document
September 03, 2026 Filed Sep 3, 2026 23:21 UTC	Entrada Therapeutics, Inc. TRDA · Entity 2163	SaleCommon Stock	32,263	$7.17	$231,325.71	Disclosure SEC source: 0001231919-26-001143 · form4-09032026_110951.xml · nonDerivative · entry 3 MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner EVNIN LUKE · CIK 0001134657 · 10% owner GADICKE ANSBERT · CIK 0001134655 · 10% owner Foley Todd · CIK 0001473930 · 10% owner MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner MPM BIOVENTURES 2018 (B), L.P. · CIK 0001729504 · 10% owner MPM ASSET MANAGEMENT INVESTORS BV2018 LLC · CIK 0001734817 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 4,144,952 F8 · shares: The shares were sold as follows: 14,650 by BV 2014, 977 by BV 2014(B), 504 by AM BV2014, 15,036 by BV 2018, 799 by BV 2018(B) and 297 by AM BV2018. F9 · price: Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.0434 to $7.405 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F4 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. F10 · ownership.nature: The shares are held as follows: 1,882,155 by BV 2014, 125,536 by BV 2014(B), 64,784 by AM BV2014, 1,931,685 by BV 2018, 102,668 by BV 2018(B) and 38,124 by AM BV2018. Read SEC document
September 02, 2026 Filed Sep 3, 2026 23:21 UTC	Entrada Therapeutics, Inc. TRDA · Entity 2163	SaleCommon Stock	25,131	$7.19	$180,691.89	Disclosure SEC source: 0001231919-26-001143 · form4-09032026_110951.xml · nonDerivative · entry 2 MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner EVNIN LUKE · CIK 0001134657 · 10% owner GADICKE ANSBERT · CIK 0001134655 · 10% owner Foley Todd · CIK 0001473930 · 10% owner MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner MPM BIOVENTURES 2018 (B), L.P. · CIK 0001729504 · 10% owner MPM ASSET MANAGEMENT INVESTORS BV2018 LLC · CIK 0001734817 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 4,177,215 F5 · shares: The shares were sold as follows: 11,412 by BV 2014, 761 by BV 2014(B), 393 by AM BV2014, 11,712 by BV 2018, 622 by BV 2018(B) and 231 by AM BV2018. F6 · price: Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.9601 to $7.3273 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F4 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. F7 · ownership.nature: The shares are held as follows: 1,896,805 by BV 2014, 126,513 by BV 2014(B), 65,288 by AM BV2014, 1,946,721 by BV 2018, 103,467 by BV 2018(B) and 38,421 by AM BV2018. Read SEC document
September 01, 2026 Filed Sep 3, 2026 23:21 UTC	Entrada Therapeutics, Inc. TRDA · Entity 2163	SaleCommon Stock	29,088	$7.06	$205,361.28	Disclosure SEC source: 0001231919-26-001143 · form4-09032026_110951.xml · nonDerivative · entry 1 MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner EVNIN LUKE · CIK 0001134657 · 10% owner GADICKE ANSBERT · CIK 0001134655 · 10% owner Foley Todd · CIK 0001473930 · 10% owner MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner MPM BIOVENTURES 2018 (B), L.P. · CIK 0001729504 · 10% owner MPM ASSET MANAGEMENT INVESTORS BV2018 LLC · CIK 0001734817 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 4,202,346 F1 · shares: The shares were sold as follows: 13,208 by MPM BioVentures 2014, L.P. ("BV 2014"), 881 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 455 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 13,556 by MPM BioVentures 2018, L.P. ("BV 2018"), 720 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 268 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC. F2 · price: Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.80 to $7.15 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F3 · ownership.nature: The shares are held as follows: 1,908,217 by BV 2014, 127,274 by BV 2014(B), 65,681 by AM BV2014, 1,958,433 by BV 2018, 104,089 by BV 2018(B) and 38,652 by AM BV2018. F4 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. Read SEC document
August 31, 2026 Filed Aug 31, 2026 22:25 UTC	Entrada Therapeutics, Inc. TRDA · Entity 2163	SaleCommon Stock	44,259	$6.99	$309,370.41	Disclosure SEC source: 0001231919-26-001135 · form4-08312026_100852.xml · nonDerivative · entry 3 MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner EVNIN LUKE · CIK 0001134657 · 10% owner GADICKE ANSBERT · CIK 0001134655 · 10% owner Foley Todd · CIK 0001473930 · 10% owner MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner MPM BIOVENTURES 2018 (B), L.P. · CIK 0001729504 · 10% owner MPM ASSET MANAGEMENT INVESTORS BV2018 LLC · CIK 0001734817 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 4,231,434 F8 · shares: The shares were sold as follows: 20,097 by BV 2014, 1,341 by BV 2014(B), 692 by AM BV2014, 20,626 by BV 2018, 1,096 by BV 2018(B) and 407 by AM BV2018. F9 · price: Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.76 to $7.1626 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F4 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. F10 · ownership.nature: The shares are held as follows: 1,921,425 by BV 2014, 128,155 by BV 2014(B), 66,136 by AM BV2014, 1,971,989 by BV 2018, 104,809 by BV 2018(B) and 38,920 by AM BV2018. Read SEC document
August 28, 2026 Filed Aug 31, 2026 22:25 UTC	Entrada Therapeutics, Inc. TRDA · Entity 2163	SaleCommon Stock	3,733	$7.01	$26,168.33	Disclosure SEC source: 0001231919-26-001135 · form4-08312026_100852.xml · nonDerivative · entry 2 MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner EVNIN LUKE · CIK 0001134657 · 10% owner GADICKE ANSBERT · CIK 0001134655 · 10% owner Foley Todd · CIK 0001473930 · 10% owner MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner MPM BIOVENTURES 2018 (B), L.P. · CIK 0001729504 · 10% owner MPM ASSET MANAGEMENT INVESTORS BV2018 LLC · CIK 0001734817 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 4,275,693 F5 · shares: The shares were sold as follows: 1,695 by BV 2014, 113 by BV 2014(B), 58 by AM BV2014, 1,740 by BV 2018, 93 by BV 2018(B) and 34 by AM BV2018. F6 · price: Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.95 to $7.24 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F4 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. F7 · ownership.nature: The shares are held as follows: 1,941,522 by BV 2014, 129,496 by BV 2014(B), 66,828 by AM BV2014, 1,992,615 by BV 2018, 105,905 by BV 2018(B) and 39,327 by AM BV2018. Read SEC document
August 27, 2026 Filed Aug 31, 2026 22:25 UTC	Entrada Therapeutics, Inc. TRDA · Entity 2163	SaleCommon Stock	38,922	$7.20	$280,238.40	Disclosure SEC source: 0001231919-26-001135 · form4-08312026_100852.xml · nonDerivative · entry 1 MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner EVNIN LUKE · CIK 0001134657 · 10% owner GADICKE ANSBERT · CIK 0001134655 · 10% owner Foley Todd · CIK 0001473930 · 10% owner MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner MPM BIOVENTURES 2018 (B), L.P. · CIK 0001729504 · 10% owner MPM ASSET MANAGEMENT INVESTORS BV2018 LLC · CIK 0001734817 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 4,279,426 F1 · shares: The shares were sold as follows: 17,674 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,179 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 608 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 18,139 by MPM BioVentures 2018, L.P. ("BV 2018"), 964 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 358 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC. F2 · price: Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.88 to $7.37 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F3 · ownership.nature: The shares are held as follows: 1,943,217 by BV 2014, 129,609 by BV 2014(B), 66,886 by AM BV2014, 1,994,355 by BV 2018, 105,998 by BV 2018(B) and 39,361 by AM BV2018. F4 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. Read SEC document
August 26, 2026 Filed Aug 27, 2026 01:28 UTC	Entrada Therapeutics, Inc. TRDA · Entity 2163	SaleCommon Stock	14,569	$7.06	$102,857.14	Disclosure SEC source: 0001231919-26-001107 · form4-08272026_010802.xml · nonDerivative · entry 3 MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner EVNIN LUKE · CIK 0001134657 · 10% owner GADICKE ANSBERT · CIK 0001134655 · 10% owner Foley Todd · CIK 0001473930 · 10% owner MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner MPM BIOVENTURES 2018 (B), L.P. · CIK 0001729504 · 10% owner MPM ASSET MANAGEMENT INVESTORS BV2018 LLC · CIK 0001734817 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 4,318,348 F8 · shares: The shares were sold as follows: 6,615 by BV 2014, 441 by BV 2014(B), 228 by AM BV2014, 6,790 by BV 2018, 361 by BV 2018(B) and 134 by AM BV2018. F9 · price: Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.97 to $7.55 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F4 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. F10 · ownership.nature: The shares are held as follows: 1,960,891 by BV 2014, 130,788 by BV 2014(B), 67,494 by AM BV2014, 2,012,494 by BV 2018, 106,962 by BV 2018(B) and 39,719 by AM BV2018. Read SEC document
August 25, 2026 Filed Aug 27, 2026 01:28 UTC	Entrada Therapeutics, Inc. TRDA · Entity 2163	SaleCommon Stock	26,522	$7.54	$199,975.88	Disclosure SEC source: 0001231919-26-001107 · form4-08272026_010802.xml · nonDerivative · entry 2 MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner EVNIN LUKE · CIK 0001134657 · 10% owner GADICKE ANSBERT · CIK 0001134655 · 10% owner Foley Todd · CIK 0001473930 · 10% owner MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner MPM BIOVENTURES 2018 (B), L.P. · CIK 0001729504 · 10% owner MPM ASSET MANAGEMENT INVESTORS BV2018 LLC · CIK 0001734817 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 4,332,917 F5 · shares: The shares were sold as follows: 12,043 by BV 2014, 803 by BV 2014(B), 415 by AM BV2014, 12,360 by BV 2018, 657 by BV 2018(B) and 244 by AM BV2018. F6 · price: Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.28 to $7.6421 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F4 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. F7 · ownership.nature: The shares are held as follows: 1,967,506 by BV 2014, 131,229 by BV 2014(B), 67,722 by AM BV2014, 2,019,284 by BV 2018, 107,323 by BV 2018(B) and 39,853 by AM BV2018. Read SEC document
August 24, 2026 Filed Aug 27, 2026 01:28 UTC	Entrada Therapeutics, Inc. TRDA · Entity 2163	SaleCommon Stock	21,623	$7.34	$158,712.82	Disclosure SEC source: 0001231919-26-001107 · form4-08272026_010802.xml · nonDerivative · entry 1 MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner EVNIN LUKE · CIK 0001134657 · 10% owner GADICKE ANSBERT · CIK 0001134655 · 10% owner Foley Todd · CIK 0001473930 · 10% owner MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner MPM BIOVENTURES 2018 (B), L.P. · CIK 0001729504 · 10% owner MPM ASSET MANAGEMENT INVESTORS BV2018 LLC · CIK 0001734817 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 4,359,439 F1 · shares: The shares were sold as follows: 9,819 by MPM BioVentures 2014, L.P. ("BV 2014"), 655 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 338 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 10,077 by MPM BioVentures 2018, L.P. ("BV 2018"), 535 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 199 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC. F2 · price: Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.0852 to $7.58 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F3 · ownership.nature: The shares are held as follows: 1,979,549 by BV 2014, 132,032 by BV 2014(B), 68,137 by AM BV2014, 2,031,644 by BV 2018, 107,980 by BV 2018(B) and 40,097 by AM BV2018. F4 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. Read SEC document
January 12, 2026 Filed Jan 14, 2026 23:17 UTC	Aktis Oncology, Inc. AKTS · Entity 4711	ConversionSeries B Redeemable Convertible Preferred Stock · Derivative	6,000,000	$0.00	$0.00	Disclosure SEC source: 0001231919-26-000055 · form4-01142026_110148.xml · derivative · entry 7 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Oncology Impact Private Investment Fund 2, L.P. · CIK 0002104306 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,577,119 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F2 · price: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F2 · derivative.exercise_date: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F2 · derivative.expiration_date: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F3 · ownership.nature: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F7 · ownership.nature: The shares of common stock were issued upon conversion as follows: 668,173 by BV 2018, 35,512 by BV 2018(B), 13,187 by AM BV2018, 143,374 by MPM Oncology and 716,873 by MPM Oncology Impact. Read SEC document
January 12, 2026 Filed Jan 14, 2026 23:17 UTC	Aktis Oncology, Inc. AKTS · Entity 4711	ConversionSeries A Redeemable Convertible Preferred Stock · Derivative	22,500,000	$0.00	$0.00	Disclosure SEC source: 0001231919-26-000055 · form4-01142026_110148.xml · derivative · entry 6 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Oncology Impact Private Investment Fund 2, L.P. · CIK 0002104306 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 5,914,197 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F2 · price: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F2 · derivative.exercise_date: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F2 · derivative.expiration_date: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F3 · ownership.nature: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F5 · ownership.nature: The shares of common stock were issued upon conversion as follows: 2,505,648 by BV 2018, 133,170 by BV 2018(B), 49,452 by AM BV2018, 537,654 by MPM Oncology and 2,688,273 by MPM Oncology Impact. Read SEC document
January 12, 2026 Filed Jan 14, 2026 23:17 UTC	Aktis Oncology, Inc. AKTS · Entity 4711	ConversionSeries Seed Redeemable Convertible Preferred Stock · Derivative	5,000,000	$0.00	$0.00	Disclosure SEC source: 0001231919-26-000055 · form4-01142026_110148.xml · derivative · entry 5 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Oncology Impact Private Investment Fund 2, L.P. · CIK 0002104306 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,314,262 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F2 · price: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F2 · derivative.exercise_date: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F2 · derivative.expiration_date: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F1 · ownership.nature: The shares of common stock were issued upon conversion as follows: 556,810 by MPM BioVentures 2018, L.P. ("BV 2018"), 29,593 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"), 10,988 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"), 119,478 by MPM Oncology Innovations Fund, L.P. ("MPM Oncology") and 597,393 by Oncology Impact Private Investment Fund 2, L.P. ("MPM Oncology Impact"). MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Drs. Evnin and Gadicke are managing directors of BV 2018 LLC and managers of MPM Oncology Innovations Fund GP LLC, which is the general partner of MPM Oncology. Dr. Gadicke is the managing member of MPM Oncology Investments 2 LLC, which is the general partner of MPM Oncology Impact. F3 · ownership.nature: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document
January 12, 2026 Filed Jan 14, 2026 23:17 UTC	Aktis Oncology, Inc. AKTS · Entity 4711	PurchaseCommon Stock	1,112,777	$18.00	$20,029,986.00	Disclosure SEC source: 0001231919-26-000055 · form4-01142026_110148.xml · nonDerivative · entry 4 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Oncology Impact Private Investment Fund 2, L.P. · CIK 0002104306 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 10,260,064 F9 · shares: The shares were purchased as follows: 219,897 by BV 2018, 8,689 by BV 2018(B), 4,284 by AM BV2018, 46,574 by MPM Oncology and 833,333 by MPM Oncology Impact. F3 · ownership.nature: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F10 · ownership.nature: The shares are held as follows: 341,709 by MPM AM, 3,950,528 by BV 2018, 206,964 by BV 2018(B), 77,911 by AM BV2018, 847,080 by MPM Oncology and 4,835,872 by MPM Oncology Impact. Read SEC document
January 12, 2026 Filed Jan 14, 2026 23:17 UTC	Aktis Oncology, Inc. AKTS · Entity 4711	ConversionCommon Stock	1,577,119	Not disclosed	Not disclosed	Disclosure SEC source: 0001231919-26-000055 · form4-01142026_110148.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Oncology Impact Private Investment Fund 2, L.P. · CIK 0002104306 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 9,147,287 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · shares: The shares of common stock were issued upon conversion as follows: 668,173 by BV 2018, 35,512 by BV 2018(B), 13,187 by AM BV2018, 143,374 by MPM Oncology and 716,873 by MPM Oncology Impact. F2 · price: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F3 · ownership.nature: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F8 · ownership.nature: The shares are held as follows: 341,709 by MPM AM, 3,730,631 by BV 2018, 198,275 by BV 2018(B), 73,627 by AM BV2018, 800,506 by MPM Oncology and 4,002,539 by MPM Oncology Impact. Read SEC document
January 12, 2026 Filed Jan 14, 2026 23:17 UTC	Aktis Oncology, Inc. AKTS · Entity 4711	ConversionCommon Stock	5,914,197	Not disclosed	Not disclosed	Disclosure SEC source: 0001231919-26-000055 · form4-01142026_110148.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Oncology Impact Private Investment Fund 2, L.P. · CIK 0002104306 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 7,570,168 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · shares: The shares of common stock were issued upon conversion as follows: 2,505,648 by BV 2018, 133,170 by BV 2018(B), 49,452 by AM BV2018, 537,654 by MPM Oncology and 2,688,273 by MPM Oncology Impact. F2 · price: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F3 · ownership.nature: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F6 · ownership.nature: The shares are held as follows: 341,709 by MPM AM, 3,062,458 by BV 2018, 162,763 by BV 2018(B), 60,440 by AM BV2018, 657,132 by MPM Oncology and 3,285,666 by MPM Oncology Impact. Read SEC document
January 12, 2026 Filed Jan 14, 2026 23:17 UTC	Aktis Oncology, Inc. AKTS · Entity 4711	ConversionCommon Stock	1,314,262	Not disclosed	Not disclosed	Disclosure SEC source: 0001231919-26-000055 · form4-01142026_110148.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Oncology Impact Private Investment Fund 2, L.P. · CIK 0002104306 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 1,655,971 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The shares of common stock were issued upon conversion as follows: 556,810 by MPM BioVentures 2018, L.P. ("BV 2018"), 29,593 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"), 10,988 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"), 119,478 by MPM Oncology Innovations Fund, L.P. ("MPM Oncology") and 597,393 by Oncology Impact Private Investment Fund 2, L.P. ("MPM Oncology Impact"). MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Drs. Evnin and Gadicke are managing directors of BV 2018 LLC and managers of MPM Oncology Innovations Fund GP LLC, which is the general partner of MPM Oncology. Dr. Gadicke is the managing member of MPM Oncology Investments 2 LLC, which is the general partner of MPM Oncology Impact. F2 · price: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F3 · ownership.nature: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F4 · ownership.nature: The shares are held as follows: 341,709 by MPM Asset Management LLC ("MPM AM"), 556,810 by BV 2018, 29,593 by BV 2018(B), 10,988 by AM BV2018, 119,478 by MPM Oncology and 597,393 by MPM Oncology Impact. Dr. Gadicke is the manager of MPM AM. Read SEC document
December 04, 2025 Filed Dec 4, 2025 23:18 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	83,230	$0.97	$80,733.10	Disclosure SEC source: 0001231919-25-000574 · form4-12042025_111237.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · Former 10% Owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · Former 10% Owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · Former 10% Owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · Former 10% Owner MPM BioImpact LLC · CIK 0001687078 · Former 10% Owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · Former 10% Owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 4,784,111 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F9 · shares: The shares were sold as follows: 5,714 by AM LLC, 36,101 by BV 2014, 2,408 by BV 2014(B), 1,243 by AM BV2014, 7,950 by MPM OIF and 29,814 by UBS Oncology. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.92 to $1.0208 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F11 · ownership.nature: The shares are held as follows: 328,588 by AM LLC, 2,075,004 by BV 2014, 138,399 by BV 2014(B), 71,421 by AM BV2014, 454,866 by MPM OIF and 1,715,833 by UBS Oncology. Read SEC document
December 03, 2025 Filed Dec 4, 2025 23:18 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	57,225	$0.87	$49,785.75	Disclosure SEC source: 0001231919-25-000574 · form4-12042025_111237.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · Former 10% Owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · Former 10% Owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · Former 10% Owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · Former 10% Owner MPM BioImpact LLC · CIK 0001687078 · Former 10% Owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · Former 10% Owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 4,867,341 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F6 · shares: The shares were sold as follows: 3,929 by AM LLC, 24,821 by BV 2014, 1,656 by BV 2014(B), 854 by AM BV2014, 5,466 by MPM OIF and 20,499 by UBS Oncology. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.9256 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F8 · ownership.nature: The shares are held as follows: 334,302 by AM LLC, 2,111,105 by BV 2014, 140,807 by BV 2014(B), 72,664 by AM BV2014, 462,816 by MPM OIF and 1,745,647 by UBS Oncology. Read SEC document
December 02, 2025 Filed Dec 4, 2025 23:18 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	59,277	$0.89	$52,756.53	Disclosure SEC source: 0001231919-25-000574 · form4-12042025_111237.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · Former 10% Owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · Former 10% Owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · Former 10% Owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · Former 10% Owner MPM BioImpact LLC · CIK 0001687078 · Former 10% Owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · Former 10% Owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 4,924,566 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F2 · shares: The shares were sold as follows: 4,070 by MPM Asset Management LLC ("AM LLC"), 25,712 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,715 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 884 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 5,662 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 21,234 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.852 to $0.9246 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F5 · ownership.nature: The shares are held as follows: 338,231 by AM LLC, 2,135,926 by BV 2014, 142,463 by BV 2014(B), 73,518 by AM BV2014, 468,282 by MPM OIF and 1,766,146 by UBS Oncology. Read SEC document
December 01, 2025 Filed Dec 1, 2025 23:11 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	60,917	$0.94	$57,261.98	Disclosure SEC source: 0001231919-25-000564 · form4-12012025_111253.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 4,983,843 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F9 · shares: The shares were sold as follows: 4,182 by AM LLC, 26,423 by BV 2014, 1,762 by BV 2014(B), 910 by AM BV2014, 5,819 by MPM OIF and 21,821 by UBS Oncology. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.905 to $1.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F11 · ownership.nature: The shares are held as follows: 342,301 by AM LLC, 2,161,638 by BV 2014, 144,178 by BV 2014(B), 74,402 by AM BV2014, 473,944 by MPM OIF and 1,787,380 by UBS Oncology. Read SEC document
November 28, 2025 Filed Dec 1, 2025 23:11 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	20,277	$0.99	$20,074.23	Disclosure SEC source: 0001231919-25-000564 · form4-12012025_111253.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 5,044,760 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F6 · shares: The shares were sold as follows: 1,392 by AM LLC, 8,795 by BV 2014, 587 by BV 2014(B), 303 by AM BV2014, 1,937 by MPM OIF and 7,263 by UBS Oncology. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9681 to $1.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F8 · ownership.nature: The shares are held as follows: 346,483 by AM LLC, 2,188,061 by BV 2014, 145,940 by BV 2014(B), 75,312 by AM BV2014, 479,763 by MPM OIF and 1,809,201 by UBS Oncology. Read SEC document
November 26, 2025 Filed Dec 1, 2025 23:11 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	60,733	$0.98	$59,518.34	Disclosure SEC source: 0001231919-25-000564 · form4-12012025_111253.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 5,065,037 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F2 · shares: The shares were sold as follows: 4,170 by MPM Asset Management LLC ("AM LLC"), 26,343 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,757 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 907 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 5,801 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 21,755 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9328 to $1.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F5 · ownership.nature: The shares are held as follows: 347,875 by AM LLC, 2,196,856 by BV 2014, 146,527 by BV 2014(B), 75,615 by AM BV2014, 481,700 by MPM OIF and 1,816,464 by UBS Oncology. Read SEC document
November 25, 2025 Filed Nov 25, 2025 23:03 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	42,533	$0.92	$39,130.36	Disclosure SEC source: 0001231919-25-000550 · form4-11252025_111145.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 5,125,770 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F9 · shares: The shares were sold as follows: 2,920 by AM LLC, 18,449 by BV 2014, 1,230 by BV 2014(B), 635 by AM BV2014, 4,063 by MPM OIF and 15,236 by UBS Oncology. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.90 to $0.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F11 · ownership.nature: The shares are held as follows: 352,045 by AM LLC, 2,223,199 by BV 2014, 148,284 by BV 2014(B), 76,522 by AM BV2014, 487,501 by MPM OIF and 1,838,219 by UBS Oncology. Read SEC document
November 24, 2025 Filed Nov 25, 2025 23:03 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	88,802	$0.98	$87,025.96	Disclosure SEC source: 0001231919-25-000550 · form4-11252025_111145.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 5,168,303 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F6 · shares: The shares were sold as follows: 6,097 by AM LLC, 38,518 by BV 2014, 2,569 by BV 2014(B), 1,325 by AM BV2014, 8,483 by MPM OIF and 31,810 by UBS Oncology. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.8733 to $1.03 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F8 · ownership.nature: The shares are held as follows: 354,965 by AM LLC, 2,241,648 by BV 2014, 149,514 by BV 2014(B), 77,157 by AM BV2014, 491,564 by MPM OIF and 1,853,455 by UBS Oncology. Read SEC document
November 21, 2025 Filed Nov 25, 2025 23:03 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	64,331	$0.83	$53,394.73	Disclosure SEC source: 0001231919-25-000550 · form4-11252025_111145.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 5,257,105 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F2 · shares: The shares were sold as follows: 4,417 by MPM Asset Management LLC ("AM LLC"), 27,904 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,861 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 960 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 6,145 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 23,044 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.80 to $0.8861 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F5 · ownership.nature: The shares are held as follows: 361,062 by AM LLC, 2,280,166 by BV 2014, 152,083 by BV 2014(B), 78,482 by AM BV2014, 500,047 by MPM OIF and 1,885,265 by UBS Oncology. Read SEC document
November 20, 2025 Filed Nov 20, 2025 22:50 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	41,152	$0.89	$36,625.28	Disclosure SEC source: 0001231919-25-000533 · form4-11202025_101121.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 5,321,436 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F9 · shares: The shares were sold as follows: 2,825 by AM LLC, 17,850 by BV 2014, 1,191 by BV 2014(B), 614 by AM BV2014, 3,931 by MPM OIF and 14,741 by UBS Oncology. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.8506 to $0.9556 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F11 · ownership.nature: The shares are held as follows: 365,479 by AM LLC, 2,308,070 by BV 2014, 153,944 by BV 2014(B), 79,442 by AM BV2014, 506,192 by MPM OIF and 1,908,309 by UBS Oncology. Read SEC document
November 19, 2025 Filed Nov 20, 2025 22:50 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	66,324	$0.94	$62,344.56	Disclosure SEC source: 0001231919-25-000533 · form4-11202025_101121.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 5,362,588 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F6 · shares: The shares were sold as follows: 4,554 by AM LLC, 28,768 by BV 2014, 1,919 by BV 2014(B), 990 by AM BV2014, 6,335 by MPM OIF and 23,758 by UBS Oncology. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.901 to $0.9806 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F8 · ownership.nature: The shares are held as follows: 368,304 by AM LLC, 2,325,920 by BV 2014, 155,135 by BV 2014(B), 80,056 by AM BV2014, 510,123 by MPM OIF and 1,923,050 by UBS Oncology. Read SEC document
November 18, 2025 Filed Nov 20, 2025 22:50 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	52,627	$0.93	$48,943.11	Disclosure SEC source: 0001231919-25-000533 · form4-11202025_101121.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 5,428,912 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F2 · shares: The shares were sold as follows: 3,613 by MPM Asset Management LLC ("AM LLC"), 22,827 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,523 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 786 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 5,027 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 18,851 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.8902 to $0.9601 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F5 · ownership.nature: The shares are held as follows: 372,858 by AM LLC, 2,354,688 by BV 2014, 157,054 by BV 2014(B), 81,046 by AM BV2014, 516,458 by MPM OIF and 1,946,808 by UBS Oncology. Read SEC document
November 17, 2025 Filed Nov 18, 2025 00:20 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	57,061	$0.95	$54,207.95	Disclosure SEC source: 0001231919-25-000507 · form4-11182025_121121.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 5,481,539 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F9 · shares: The shares were sold as follows: 3,918 by AM LLC, 24,750 by BV 2014, 1,651 by BV 2014(B), 851 by AM BV2014, 5,451 by MPM OIF and 20,440 by UBS Oncology. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9183 to $0.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F11 · ownership.nature: The shares are held as follows: 376,471 by AM LLC, 2,377,515 by BV 2014, 158,577 by BV 2014(B), 81,832 by AM BV2014, 521,485 by MPM OIF and 1,965,659 by UBS Oncology. Read SEC document
November 14, 2025 Filed Nov 18, 2025 00:20 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	61,640	$0.93	$57,325.20	Disclosure SEC source: 0001231919-25-000507 · form4-11182025_121121.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 5,538,600 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F6 · shares: The shares were sold as follows: 4,232 by AM LLC, 26,736 by BV 2014, 1,783 by BV 2014(B), 921 by AM BV2014, 5,888 by MPM OIF and 22,080 by UBS Oncology. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.895 to $0.9551 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F8 · ownership.nature: The shares are held as follows: 380,389 by AM LLC, 2,402,265 by BV 2014, 160,228 by BV 2014(B), 82,683 by AM BV2014, 526,936 by MPM OIF and 1,986,099 by UBS Oncology. Read SEC document
November 13, 2025 Filed Nov 18, 2025 00:20 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	90,951	$0.98	$89,131.98	Disclosure SEC source: 0001231919-25-000507 · form4-11182025_121121.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 5,600,240 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F2 · shares: The shares were sold as follows: 6,244 by MPM Asset Management LLC ("AM LLC"), 39,450 by MPM BioVentures 2014, L.P. ("BV 2014"), 2,631 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 1,359 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 8,688 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 32,579 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.918 to $1.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F5 · ownership.nature: The shares are held as follows: 384,621 by AM LLC, 2,429,001 by BV 2014, 162,011 by BV 2014(B), 83,604 by AM BV2014, 532,824 by MPM OIF and 2,008,179 by UBS Oncology. Read SEC document
November 12, 2025 Filed Nov 13, 2025 00:31 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	40,669	$1.09	$44,329.21	Disclosure SEC source: 0001231919-25-000459 · form4-11132025_121146.xml · nonDerivative · entry 4 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 5,691,191 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F12 · shares: The shares were sold as follows: 2,792 by AM LLC, 17,640 by BV 2014, 1,177 by BV 2014(B), 607 by AM BV2014, 3,885 by MPM OIF and 14,568 by UBS Oncology. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.065 to $1.145 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F14 · ownership.nature: The shares are held as follows: 390,865 by AM LLC, 2,468,451 by BV 2014, 164,642 by BV 2014(B), 84,963 by AM BV2014, 541,512 by MPM OIF and 2,040,758 by UBS Oncology. Read SEC document
November 11, 2025 Filed Nov 13, 2025 00:31 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	55,810	$1.14	$63,623.40	Disclosure SEC source: 0001231919-25-000459 · form4-11132025_121146.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 5,731,860 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F9 · shares: The shares were sold as follows: 3,832 by AM LLC, 24,208 by BV 2014, 1,615 by BV 2014(B), 832 by AM BV2014, 5,331 by MPM OIF and 19,992 by UBS Oncology. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.115 to $1.17 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F11 · ownership.nature: The shares are held as follows: 393,657 by AM LLC, 2,486,091 by BV 2014, 165,819 by BV 2014(B), 85,570 by AM BV2014, 545,397 by MPM OIF and 2,055,326 by UBS Oncology. Read SEC document
November 10, 2025 Filed Nov 13, 2025 00:31 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	48,570	$1.18	$57,312.60	Disclosure SEC source: 0001231919-25-000459 · form4-11132025_121146.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 5,787,670 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F6 · shares: The shares were sold as follows: 3,335 by AM LLC, 21,067 by BV 2014, 1,405 by BV 2014(B), 725 by AM BV2014, 4,640 by MPM OIF and 17,398 by UBS Oncology. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.145 to $1.21 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F8 · ownership.nature: The shares are held as follows: 397,489 by AM LLC, 2,510,299 by BV 2014, 167,434 by BV 2014(B), 86,402 by AM BV2014, 550,728 by MPM OIF and 2,075,318 by UBS Oncology. Read SEC document
November 07, 2025 Filed Nov 13, 2025 00:31 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	68,480	$1.11	$76,012.80	Disclosure SEC source: 0001231919-25-000459 · form4-11132025_121146.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 5,836,240 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F2 · shares: The shares were sold as follows: 4,702 by MPM Asset Management LLC ("AM LLC"), 29,704 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,981 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 1,022 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 6,541 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 24,530 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.075 to $1.188 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F5 · ownership.nature: The shares are held as follows: 400,824 by AM LLC, 2,531,366 by BV 2014, 168,839 by BV 2014(B), 87,127 by AM BV2014, 555,368 by MPM OIF and 2,092,716 by UBS Oncology. Read SEC document
November 06, 2025 Filed Nov 7, 2025 00:40 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	54,452	$1.21	$65,886.92	Disclosure SEC source: 0001231919-25-000439 · form4-11072025_121138.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 5,904,720 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F9 · shares: The shares were sold as follows: 3,738 by AM LLC, 23,619 by BV 2014, 1,575 by BV 2014(B), 814 by AM BV2014, 5,201 by MPM OIF and 19,505 by UBS Oncology. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.185 to $1.27 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F11 · ownership.nature: The shares are held as follows: 405,526 by AM LLC, 2,561,070 by BV 2014, 170,820 by BV 2014(B), 88,149 by AM BV2014, 561,909 by MPM OIF and 2,117,246 by UBS Oncology. Read SEC document
November 05, 2025 Filed Nov 7, 2025 00:40 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	47,950	$1.22	$58,499.00	Disclosure SEC source: 0001231919-25-000439 · form4-11072025_121138.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 5,959,172 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F6 · shares: The shares were sold as follows: 3,292 by AM LLC, 20,798 by BV 2014, 1,387 by BV 2014(B), 717 by AM BV2014, 4,580 by MPM OIF and 17,176 by UBS Oncology. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.19 to $1.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F8 · ownership.nature: The shares are held as follows: 409,264 by AM LLC, 2,584,689 by BV 2014, 172,395 by BV 2014(B), 88,963 by AM BV2014, 567,110 by MPM OIF and 2,136,751 by UBS Oncology. Read SEC document
November 04, 2025 Filed Nov 7, 2025 00:40 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	140,488	$1.22	$171,395.36	Disclosure SEC source: 0001231919-25-000439 · form4-11072025_121138.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 6,007,122 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F2 · shares: The shares were sold as follows: 9,645 by MPM Asset Management LLC ("AM LLC"), 60,937 by MPM BioVentures 2014, L.P. ("BV 2014"), 4,064 by MPM BioVentures 2014(B), L.P. (BV 2014(B), 2,098 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 13,420 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 50,324 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC and a manager of MPM OIF GP. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F3 · shares: MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.17 to $1.30 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: The shares are held as follows: 412,556 by AM LLC, 2,605,487 by BV 2014, 173,782 by BV 2014(B), 89,680 by AM BV2014, 571,690 by MPM OIF and 2,153,927 by UBS Oncology. Read SEC document
November 03, 2025 Filed Nov 4, 2025 00:07 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	94,063	$1.29	$121,341.27	Disclosure SEC source: 0001231919-25-000404 · form4-11042025_121157.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 6,147,610 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F9 · shares: The shares were sold as follows: 6,458 by AM LLC, 40,800 by BV 2014, 2,721 by BV 2014(B), 1,405 by AM BV2014, 8,985 by MPM OIF and 33,694 by UBS Oncology. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.245 to $1.33 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F11 · ownership.nature: The shares are held as follows: 422,201 by AM LLC, 2,666,424 by BV 2014, 177,846 by BV 2014(B), 91,778 by AM BV2014, 585,110 by MPM OIF and 2,204,251 by UBS Oncology. Read SEC document
October 31, 2025 Filed Nov 4, 2025 00:07 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	114,044	$1.28	$145,976.32	Disclosure SEC source: 0001231919-25-000404 · form4-11042025_121157.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 6,241,673 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F6 · shares: The shares were sold as follows: 7,830 by AM LLC, 49,467 by BV 2014, 3,299 by BV 2014(B), 1,702 by AM BV2014, 10,894 by MPM OIF and 40,852 by UBS Oncology. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.205 to $1.415 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F8 · ownership.nature: The shares are held as follows: 428,659 by AM LLC, 2,707,224 by BV 2014, 180,567 by BV 2014(B), 93,183 by AM BV2014, 594,095 by MPM OIF and 2,237,945 by UBS Oncology. Read SEC document
October 30, 2025 Filed Nov 4, 2025 00:07 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	86,936	$1.43	$124,318.48	Disclosure SEC source: 0001231919-25-000404 · form4-11042025_121157.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 6,355,717 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F2 · shares: The shares were sold as follows: 5,969 by MPM Asset Management LLC ("AM LLC"), 37,709 by MPM BioVentures 2014, L.P. ("BV 2014"), 2,515 by MPM BioVentures 2014(B), L.P. (BV 2014(B), 1,298 MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 8,304 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 31,141 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC and a manager of MPM OIF GP. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F3 · shares: MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.365 to $1.55 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: The shares are held as follows: 436,489 by AM LLC, 2,756,691 by BV 2014, 183,866 by BV 2014(B), 94,885 by AM BV2014, 604,989 by MPM OIF and 2,278,797 by UBS Oncology. Read SEC document
October 29, 2025 Filed Oct 29, 2025 23:21 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	134,240	$1.55	$208,072.00	Disclosure SEC source: 0001231919-25-000373 · form4-10292025_111002.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 6,442,653 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F9 · shares: The shares were sold as follows: 9,216 by AM LLC, 58,227 by BV 2014, 3,884 by BV 2014(B), 2,004 by AM BV2014, 12,823 by MPM OIF and 48,086 by UBS Oncology F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.51 to $1.62 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F11 · ownership.nature: The shares are held as follows: 442,458 by AM LLC, 2,794,400 by BV 2014, 186,381 by BV 2014(B), 96,183 by AM BV2014, 613,293 by MPM OIF and 2,309,938 by UBS Oncology. Read SEC document
October 28, 2025 Filed Oct 29, 2025 23:21 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	69,068	$1.64	$113,271.52	Disclosure SEC source: 0001231919-25-000373 · form4-10292025_111002.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 6,576,893 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F6 · shares: The shares were sold as follows: 4,742 by AM LLC, 29,958 by BV 2014, 1,998 by BV 2014(B), 1,031 by AM BV2014, 6,598 by MPM OIF and 24,741 by UBS Oncology. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.605 to $1.70 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F8 · ownership.nature: The shares are held as follows: 451,674 by AM LLC, 2,852,627 by BV 2014, 190,265 by BV 2014(B), 98,187 by AM BV2014, 626,116 by MPM OIF and 2,358,024 by UBS Oncology. Read SEC document
October 27, 2025 Filed Oct 29, 2025 23:21 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	72,709	$1.72	$125,059.48	Disclosure SEC source: 0001231919-25-000373 · form4-10292025_111002.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 6,645,961 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F2 · shares: The shares were sold as follows: 4,992 by MPM Asset Management LLC ("AM LLC"), 31,538 by MPM BioVentures 2014, L.P. ("BV 2014"), 2,104 by MPM BioVentures 2014(B), L.P. (BV 2014(B), 1,085 MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 6,945 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 26,045 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC and a manager of MPM OIF GP. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F3 · shares: MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.675 to $1.82 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: The shares are held as follows: 456,416 by AM LLC, 2,882,585 by BV 2014, 192,263 by BV 2014(B), 99,218 by AM BV2014, 632,714 by MPM OIF and 2,382,765 by UBS Oncology. Read SEC document
May 13, 2025 Filed May 15, 2025 21:34 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	1,031,931	$8.06	$8,317,363.86	Disclosure SEC source: 0001415889-25-013252 · form4-05152025_090510.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · Former 10% Owner MPM BioImpact LLC · CIK 0001687078 · Former 10% Owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · Former 10% Owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 3,452,797 F1 · shares: The shares were sold as follows: 355,406 by MPM BioVentures 2014, L.P. ("BV 2014"), 22,386 by MPM BioVentures 2014 (B), L.P. ("BV 2014(B)"), 12,233 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 224,467 by MPM BioVentures 2018, L.P. ("BV 2018"), 11,267 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)"), 4,432 by MPM Asset Management Investors BV2018 LLC ("AM BV2018") and 401,740 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC. F2 · shares: MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.73 to $8.34 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The shares are held as follows: 1,189,174 by BV 2014, 74,903 by BV 2014(B), 40,931 by AM BV2014, 751,056 by BV 2018, 37,699 by BV 2018(B), 14,831 by AM BV2018 and 1,344,203 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document
March 27, 2025 Filed Apr 30, 2025 20:08 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	OtherWarrant (Right to Buy) · Derivative	42,842	$0.00 Strike: $0.09	$0.00	Disclosure SEC source: 0001415889-25-011569 · form4-04302025_080446.xml · derivative · entry 4 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 42,842 shares Expires 2025-08-13 F1 · kind: On March 27, 2025, the Reporting Persons exercised warrants to purchase an aggregate of 50,873 shares of the Company's Common Stock for $0.09 per share. The Reporting Persons paid the exercise price on a cashless basis, resulting in the Company's withholding of 4,386 of the warrant shares to pay the exercise price and issuing the remaining 46,487 shares. F5 · derivative.exercise_date: Immediately exercisable. F7 · ownership.nature: The warrants were held as follows: 17,023 by BV 2014, 1,135 by BV 2014(B), 585 by AM BV 2014, 5,355 by MPM OIF and 18,744 by UBS Oncology. Read SEC document
March 27, 2025 Filed Apr 30, 2025 20:08 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	OtherWarrant (Right to Buy) · Derivative	8,031	$0.00 Strike: $0.09	$0.00	Disclosure SEC source: 0001415889-25-011569 · form4-04302025_080446.xml · derivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner MPM BioImpact LLC · CIK 0001687078 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner MPM ASSET MANAGEMENT LLC · CIK 0001263048 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 8,031 shares Expires 2025-04-09 F1 · kind: On March 27, 2025, the Reporting Persons exercised warrants to purchase an aggregate of 50,873 shares of the Company's Common Stock for $0.09 per share. The Reporting Persons paid the exercise price on a cashless basis, resulting in the Company's withholding of 4,386 of the warrant shares to pay the exercise price and issuing the remaining 46,487 shares. F5 · derivative.exercise_date: Immediately exercisable. F6 · ownership.nature: The warrants were held as follows: 3,647 by BV 2014, 243 by BV 2014(B), 125 by AM BV 2014 and 4,016 by UBS Oncology. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.